Hope Rugo, Professor of Medicine and Director of the Breast Oncology Clinical Trials Program at the University of California at San Francisco, shared a post on X about a paper she co-authored with colleagues published in ESMO Open:
“Important RWD – as well as outcome for N1 disease. Missed opportunity to improve outcome.”
Quoting ESMO Open’s post:
“Exploring the treatment gap and outcome risks in patients with node+, high-risk, HR+, HER2- early BC: analyses of RW data in ESMO Open. Only 40% of eligible pts received adj abemaciclib. Eligible not treated: similar TNBC recurrence/mortality risk.”
Title: Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data
Authors: S.M. Tolaney, S. Sammons, A. Sandoval-Leon, J. Cortes, A.M. Liepa, B.R. Grimes, D. He, Z.L. Cui, J. Roose, W. Gathirua-Mwangi, K. Moreira, J. O’Shaughnessy, P. Neven, S.R.D. Johnston, and H.S. Rugo.
You can read the Full Article in ESMO Open.
More posts featuring Hope Rugo.
